ZyVersa CSO retiring Aug 18; annual meeting Oct 31, proposal deadline Aug 30

ZyVersa Therapeutics, Inc.

CSO Nicholas A. LaBella, Jr. notified planned retirement effective August 18, 2023.
He is expected to remain as a member of the Scientific Advisory Board post-retirement.
Company will enter a separation agreement for compensation related to his departure.
2023 annual meeting of stockholders set for Tuesday, October 31, 2023.
Deadline for stockholder proposals and director nominations is August 30, 2023.

item 5.02 item 5.08

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nicholas A. LaBella, Jr.

Chief Scientific Officer and Senior Vice President of Research and Development

ZVSA · ZyVersa Therapeutics, Inc.

Effective: 2023-08-18
Filed: August 18, 2023, 7:59 PM ET

On August 7, 2023, Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc. (the “Company”) notified the Company of his planned retirement from the Company effective August 18, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicholas A. LaBella, Jr. retired as Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc..

Action: retired
Role: Chief Scientific Officer and Senior Vice President of Research and Development

Exact text from the filing

On August 7, 2023, Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc. (the “Company”) notified the Company of his planned retirement from the Company effective August 18, 2023.

View on SEC.gov

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029441

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.